semaglutide nad+ vs semaglutide Niacinamide semaglutide: what the compound does and whether it is worth it Tirzepatide vs. Semaglutide: A Complete

Losing weight doesnt necessarily make you fitter, a new study finds.

Mounjaro is the latest GLP-1 to enter the increasingly crowded and complex GLP-1 market, joining Ozempic (indicated for diabetes, 2017) and Wegovy (indicated for weight loss, 2021) among others

Discover how this GLP-1 weight management medication affects your stomach, learn to recognise gastritis symptoms, and find out when to seek medical advice for gastrointestinal side effects.

The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities